Radiotherapy in Combination with CD20×CD3 Bispecific Antibodies for B-Cell Lymphoma: Biological Rationale, Current Evidence, and Open Questions

Patrizia Ciammella, Alberto Bavieri, Maria Elena Nizzoli, Emanuele Alì

Open source

DOI
10.3390/cancers18172895
Published
2026-09-07
Container
Cancers
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/cancers18172895,
  title = {Radiotherapy in Combination with CD20×CD3 Bispecific Antibodies for B-Cell Lymphoma: Biological Rationale, Current Evidence, and Open Questions},
  author = {Patrizia Ciammella and Alberto Bavieri and Maria Elena Nizzoli and Emanuele Alì},
  year = {2026},
  journal = {Cancers},
  doi = {10.3390/cancers18172895},
  url = {https://doi.org/10.3390/cancers18172895}
}

RIS

TY  - JOUR
TI  - Radiotherapy in Combination with CD20×CD3 Bispecific Antibodies for B-Cell Lymphoma: Biological Rationale, Current Evidence, and Open Questions
AU  - Patrizia Ciammella
AU  - Alberto Bavieri
AU  - Maria Elena Nizzoli
AU  - Emanuele Alì
PY  - 2026
JO  - Cancers
DO  - 10.3390/cancers18172895
UR  - https://doi.org/10.3390/cancers18172895
ER  - 

APA

Ciammella, P., Bavieri, A., Nizzoli, M. E., & Alì, E. (2026). Radiotherapy in Combination with CD20×CD3 Bispecific Antibodies for B-Cell Lymphoma: Biological Rationale, Current Evidence, and Open Questions. Cancers. https://doi.org/10.3390/cancers18172895

Source records